Back to Search
Start Over
Chemical Risk Factors of Primary Liver Cancer: An Update.
- Source :
-
Hepatic medicine : evidence and research [Hepat Med] 2021 Jan 05; Vol. 12, pp. 179-188. Date of Electronic Publication: 2021 Jan 05 (Print Publication: 2020). - Publication Year :
- 2021
-
Abstract
- Primary liver cancer has the sixth highest incidence and fourth highest cancer mortality worldwide. Hepatitis B is the leading cause of liver cancer, though its incidence is decreasing with vaccination. Alcohol is the leading cause of liver transplant, cirrhosis, and cancer in the developed world, and is projected to surpass hepatitis B as the leading hepatic cancer etiology worldwide. Tobacco smoking has shown a positive association with liver cancer in a majority of studies, though not all. Aflatoxin, a mycotoxin produced by Aspergillus , is estimated to account for 3-20% of global liver cancer cases, 40% of which occur in sub-Saharan Africa. These statistics are confounded by the prevalence of hepatitis B, which may have a synergistic effect on hepatic carcinogenesis. Aflatoxin is ingested and likely inhaled from agricultural products, placing farmers, food processors, and textile workers in developing nations at risk. Vinyl-chloride is used in the production of PVC plastics and causes rare liver angiosarcoma, hepatocellular carcinoma, and other neoplasms. Arsenic and cadmium are naturally-occurring, hepatocarcinogenic metals with high occupational exposure in industries involving coal, metals, plastics, and batteries. Millions of laborers in waste-disposal and manufacturing are exposed to organic solvents and N-nitrosamines, which vary from carcinogenic (group 1) to possibly carcinogenic (group 2B) in their IARC designation. Insecticide DDT is possibly hepatocarcinogenic (group 2B), though continues to be used for malaria control in the developing world. While suggested by case reports, anabolic steroids and oral contraceptives have not been shown to increase liver cancer risk in large studies.<br />Competing Interests: Alexander Barsouk served as a consultant for Bristol-Myers Squibb. The authors declare no other conflicts of interest.<br /> (© 2020 Barsouk et al.)
Details
- Language :
- English
- ISSN :
- 1179-1535
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Hepatic medicine : evidence and research
- Publication Type :
- Academic Journal
- Accession number :
- 33447099
- Full Text :
- https://doi.org/10.2147/HMER.S278070